These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35081606)

  • 1. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
    Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
    Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.
    Liu S; Yao X; Tao J; Zhao S; Sun S; Wang S; Tian X
    J Clin Pharmacol; 2024 Aug; 64(8):1030-1043. PubMed ID: 38654529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population.
    Sukprasong R; Chuwongwattana S; Koomdee N; Jantararoungtong T; Prommas S; Jinda P; Rachanakul J; Nuntharadthanaphong N; Jongjitsook N; Puangpetch A; Sukasem C
    Sci Rep; 2021 Jun; 11(1):12343. PubMed ID: 34117307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
    Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
    Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.
    He HR; Sun JY; Ren XD; Wang TT; Zhai YJ; Chen SY; Dong YL; Lu J
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):811-9. PubMed ID: 25515945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of
    Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
    Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
    [No Abstract]   [Full Text] [Related]  

  • 9. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
    Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
    Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
    Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
    J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
    Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
    Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
    Zuo J; Xia D; Jia L; Guo T
    Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
    López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
    Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
    Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
    Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
    Hyland R; Jones BC; Smith DA
    Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
    Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.